Literature DB >> 10604328

Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.

T A Stamey1, C E Yemoto.   

Abstract

PURPOSE: We evaluated the relative usefulness of total, free and complexed serum prostate specific antigen (PSA), and their ratios for distinguishing positive from negative biopsy of prostates in a university referral practice.
MATERIALS AND METHODS: We compared 90 consecutive men who had 2 sets of 6 negative systematic biopsies with 70 who had at least 5 mm. of prostate cancer in systematic biopsies during the same period at our institution. Total prostate and transition zone volumes were determined by transrectal ultrasound. The Bayer, DPC and Hybritech assays were performed to measure total, free and complexed serum PSA. Receiver operating characteristics curves were constructed for all forms of serum PSA and their ratios as well as prostate size to distinguish true positive (sensitivity) from false-positive (1 minus specificity) fractions.
RESULTS: Complexed PSA was only marginally better than total serum PSA. Free-to-total, complexed-to-total and prostate size had highly significant areas under the curves of greater than 80%. Free PSA only was better than complexed or total PSA. When factored by prostate volume, total PSA performed as well as the PSA ratios, and transition zone volume was consistently better than total prostate volume. DPC free-to-total ratios were equivalent to Hybritech ratios in all respects.
CONCLUSIONS: Complexed PSA is only marginally better than total PSA for distinguishing negative from positive biopsy of prostates. It is inferior to free PSA and far less useful than free-to-total or complexed-to-total ratios. Prostate size is a decisive variable in men in whom we avoided the expected 25% false-negative biopsy rate in terms of specificity and hopefully avoided insignificant cancer in terms of sensitivity. In the future the performance of PSA serum markers should be related to a transition zone volume of less than 20, 20 to 60 and greater than 60 gm. when comparing assays to each other.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604328

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Complexed prostate-specific antigen improvement in detecting prostate cancer.

Authors:  K Okihara; R J Babaian
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

2.  Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

3.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

Review 4.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 5.  Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.

Authors:  S Jain; A G Bhojwani; J K Mellon
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

Review 6.  Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Authors:  Alexander Haese; Markus Graefen; Hartwig Huland; Hans Lilja
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 3.092

Review 7.  Prostate imaging features that indicate benign or malignant pathology on biopsy.

Authors:  Catherine Elizabeth Lovegrove; Mudit Matanhelia; Jagpal Randeva; David Eldred-Evans; Henry Tam; Saiful Miah; Mathias Winkler; Hashim U Ahmed; Taimur T Shah
Journal:  Transl Androl Urol       Date:  2018-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.